Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers.
Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers.
复制标题
使用新型电压门控离子通道阻滞剂针对前列腺癌进展的治疗方法。
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Milton L. Brown
中科院分区：
文献类型：
--
作者：
Robert A. Sikes;A. M. Walls;W. Brennen;James D. Anderson;Indrani Choudhury;Hilary A Schenck;Milton L. Brown
The early detection and treatment of prostate cancer have increased survival and improved clinical outcomes. The nature of the disease and pathologic understaging result in a high proportion of patients developing locally recurrent disease or distant metastases. The development of prostate cancer the time from tumor initiation and progression to invasive carcinoma often begins in men in the fourth or fifth decades of life and extends across decades. This prolonged window highlights the tremendous clinical impact that early intervention with therapeutic agents that selectively target the invasive and metastatic potential of the prostate cancer cell could have on patient survival and quality of life. Our research is currently focused on the development and testing of novel voltage-gated ion channel blockers. The expression of voltage-gated sodium channels (VGSCs) was recently associated with the metastatic behavior of prostate cancer cells. In these studies, VGSC blockers altered prostate cancer cell morphology and arrested prostate cancer cell migration. Clinically, one of the most widely used sodium channel blockers is phenytoin. We have used rational drug design based on the phenytoin binding site in a VGSC to make novel sodium channel blockers with enhanced activity and minimal acute toxicity. Our initial studies in vitro demonstrate enhanced binding of the compounds to the sodium channel and increased inhibition of prostate cancer cell growth in culture and in soft agarose compared with phenytoin. These derivatives are currently being tested for their antitumor activity in human prostate cancer xenografts.
登录
查看更多内容
影响因子：
11.2
作者：
M. Sadar;M. Gleave
通讯作者：
M. Sadar;M. Gleave
影响因子：
5.2
作者：
G L David-Beabes;M. Overman;J A Petrofski;P A Campbell;A. D. De Marzo;W G Nelson
通讯作者：
G L David-Beabes;M. Overman;J A Petrofski;P A Campbell;A. D. De Marzo;W G Nelson
Na 通道亚型具有不同的局麻药亲和力。
DOI：
10.1016/s0006-3495(96)79732-1
发表时间：
1996
期刊：
Biophysical journal.
影响因子：
--
作者：
Wang,DW;Nie,L;GeorgeJr,AL;Bennett,PB
通讯作者：
Bennett,PB
Trk 高亲和力神经生长因子受体在人前列腺中的表达。
DOI：
10.1210/endo.136.1.7828539
发表时间：
1995
期刊：
Endocrinology.
影响因子：
--
作者：
Pflug,BR;Dionne,C;Kaplan,DR;Lynch,J;Djakiew,D
通讯作者：
Djakiew,D
影响因子：
3.6
作者：
MCVARY, KT;RAZZAQ, A;MCKENNA, KE
通讯作者：
MCKENNA, KE